Cancer/Tumor Profiling Market – Exclusive Report by 360iResearch
The Global Cancer/Tumor Profiling Market to grow from USD 9.13 billion in 2022 to USD 35.94 billion by 2030, at a CAGR of 18.67%.
PUNE, MAHARASHTRA, INDIA, November 10, 2023 /EINPresswire.com/ — The “Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application – Global Forecast 2023-2030” report has been added to 360iResearch.com’s offering.
The Global Cancer/Tumor Profiling Market to grow from USD 9.13 billion in 2022 to USD 35.94 billion by 2030, at a CAGR of 18.67%.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample
Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization’s efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.
Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone’s cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient’s blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.
Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient’s genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.
Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells’ genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.
Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.
Regional Insights:
Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Cancer/Tumor Profiling Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in the Cancer/Tumor Profiling Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
Key Company Profiles:
The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..
Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire
Market Segmentation & Coverage:
This research report categorizes the Cancer/Tumor Profiling Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction. The Next-Generation Sequencing commanded largest market share of 24.12% in 2022, followed by Immunoassays.
Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker. The Genomic Biomarker commanded largest market share of 58.77% in 2022, followed by Protein Biomarker.
Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer. The Lung Cancer commanded largest market share of 23.23% in 2022, followed by Breast Cancer.
Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring. The Diagnostics commanded largest market share of 22.12% in 2022, followed by Personalized Medicine.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.45% in 2022, followed by Europe, Middle East & Africa.
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Cancer/Tumor Profiling Market, by Technology
7. Cancer/Tumor Profiling Market, by Biomarker Type
8. Cancer/Tumor Profiling Market, by Cancer Type
9. Cancer/Tumor Profiling Market, by Application
10. Americas Cancer/Tumor Profiling Market
11. Asia-Pacific Cancer/Tumor Profiling Market
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Cancer/Tumor Profiling Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Cancer/Tumor Profiling Market?
3. What is the competitive strategic window for opportunities in the Cancer/Tumor Profiling Market?
4. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?
5. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?
6. What modes and strategic moves are considered suitable for entering the Cancer/Tumor Profiling Market?
Read More @ https://www.360iresearch.com/library/intelligence/cancer-tumor-profiling?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst
Mr. Ketan Rohom
360iResearch
+1 530-264-8485
[email protected]
